{site_meta && site_meta.display_name} Logo

NewMediaWire

NewMediaWire distributes press releases on behalf of hundreds of publicly traded companies, as well as private corporations, non-profits and other public sector organizations. Founded and staffed by industry veterans, we offer a full complement of services including specialized delivery to financial sites and posting of photos and multimedia content. In addition, NewMediawire offers international and specialized services such as IR websites and industry specific distribution.

RSS Feed for NewMediaWire

Tether Supports Arcanum Capital's Fund II, Deepening Web3 Venture Capital Activities

December 26, 2024 — HAMILTON, BERMUDA - (NewMediaWire) - December 26, 2024 - Arcanum Capital ISA (“Arcanum Capital”) announced today that Tether, the issuer of the world’s largest stablecoin, has made a novel venture capital fund investment, into Arcanum Emerging Technologies Fund II (Offshore) ISA, an incorporated segregated account of DigitalArray ISAC Ltd. (the “Fund”), dedicated to nurturing the next generation of decentralized technologies.

Reconditioned pacemakers worked as well as new ones

November 17, 2024 — Research Highlights: Pacemakers reconditioned with an FDA-approved protocol worked as well as new devices in a study of nearly 300 people in seven low- and middle-income countries. The study compared the function and safety of reconditioned pacemakers to new devices at 90 days.

Email reminders improved flu shot rates in Denmark, notably among heart attack survivors

November 17, 2024 — Research Highlights: An electronic message to “nudge” patients to get a flu vaccine highlighting the cardiovascular benefits of flu shots improved vaccination rates among more than two million adults in three clinical trials in Denmark. The research observed greater improvements in vaccination, indicating that this nudge was particularly effective, among people with a history of heart attack.

Two-medication combo pill lowered blood pressure among adults in India

November 17, 2024 — Research Highlights: A study of three pills that combined two types of blood-pressure-lowering medications into one pill found that all combinations worked equally well among adults in India. Results from the TOPSPIN trial found that any two-medication combination lowered most study participants’ blood pressure to 140/90 mm Hg or less.

Spironolactone, a blood pressure medication, may help reduce risk of new heart failure

November 17, 2024 — Research Highlights: The CLEAR SYNERGY trial found that spironolactone may reduce the risk of new or worsening heart failure; however, it did not significantly impact the rate of death, new heart attack or stroke. More research is needed to further explore the potential for spironolactone, a blood pressure medication, to prevent heart failure and its long-term impact on an individual’s heart health after a heart attack.

Patients taking edoxoban after heart valve surgery had lower risk of stroke, blood clots

November 17, 2024 — Research Highlights: Edoxaban, a medication taken orally to prevent blood clots from forming, was found to be as effective and safe for stroke and blood clot prevention in patients after heart valve replacement surgery as warfarin, the current standard treatment. Unlike warfarin, edoxaban does not require regular blood tests to monitor clotting activity and does not interact with food or other medications, which simplifies treatment for patients, researchers noted.

Exenatide, a GLP-1 analog, by IV during cardiac surgery did not reduce organ injury or death

November 17, 2024 — Research Highlights: The GLORIOUS trial found that an intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) during heart surgeries involving bypass did not result in significant benefits at preventing death, stroke or organ injury compared to a placebo. Researchers noted, however, additional research is needed to determine if there are any benefits from other GLP-1 medications or from administration of exenatide for a longer period of time or at a larger dose than was tested in this study.